{
    "clinical_study": {
        "@rank": "35330", 
        "arm_group": {
            "arm_group_label": "[14C] PF 05212384", 
            "arm_group_type": "Experimental", 
            "description": "Recieve PF-05212384 89 mg Dose"
        }, 
        "brief_summary": {
            "textblock": "The purpose of the study is to characterize how PF-05212384 is metabolized in the body\n      following a single intravenous dose of radioactively labeled drug ([14C]-PF-05212384)."
        }, 
        "brief_title": "Investigation Of The Metabolism, And Excretion Of [14c]-PF-05212384 In Healthy Male Volunteers", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male subjects between the ages of 30- 65 years vasectomised or >40 with no\n             desire to father children in the near future (12 months), inclusive (Healthy is\n             defined as no clinically relevant abnormalities identified by a detailed medical\n             history, full physical examination, including blood pressure and pulse rate\n             measurement, 12 lead ECG and clinical laboratory tests).\n\n          -  Body Mass Index (BMI) of 17.5 to 35 kg/m2; and a total body weight >50 kg (110 lbs).\n\n          -  Evidence of a personally signed and dated informed consent document indicating that\n             the subject has been informed of all pertinent aspects of the study.\n\n          -  Subjects who are willing and able to comply with scheduled visits, treatment plan,\n             laboratory tests, and other study procedures.\n\n          -  Subjects agree to use an adequate method of contraception\n\n        Exclusion Criteria:\n\n          -  Evidence or history of clinically significant hematological, renal, endocrine,\n             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or\n             allergic disease (including drug allergies, but excluding untreated, asymptomatic,\n             seasonal allergies at time of dosing).\n\n          -  A positive urine drug screen or history of drug or alcohol abuse in the past 2 years."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "6", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02142920", 
            "org_study_id": "B2151006"
        }, 
        "intervention": {
            "arm_group_label": "[14C] PF 05212384", 
            "description": "Single 89 mg Dose via 30 minute IV infusion", 
            "intervention_name": "PF-05212384", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Healthy Volunteers", 
        "lastchanged_date": "May 16, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B2151006&StudyName=Investigation%20Of%20The%20Metabolism%2C%20And%20Excretion%20Of%20%5B14c%5D-PF-05212384%20In%20Healthy%20Male%20Volunteers%20"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase One, Open-Label Single-Radiolabeled Dose Study To Investigate The Metabolism, And Excretion Of [14c]-PF-05212384 In Healthy Male Volunteers", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "0.5 hours"
            }, 
            {
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "0.5 hours"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02142920"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)", 
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)", 
                "safety_issue": "No", 
                "time_frame": "9 Days"
            }, 
            {
                "description": "AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption.", 
                "measure": "Area under the Concentration-Time Curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "9 days"
            }, 
            {
                "description": "Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.", 
                "measure": "Plasma Decay Half-Life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "9 days"
            }, 
            {
                "description": "CL is a quantitative measure of the rate at which a drug substance is removed from the body.", 
                "measure": "Systemic Clearance (CL)", 
                "safety_issue": "No", 
                "time_frame": "9 days"
            }, 
            {
                "description": "Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.", 
                "measure": "Volume of Distribution at Steady State (Vss)", 
                "safety_issue": "No", 
                "time_frame": "9 days"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}